Hereditary cancer: Guidelines in clinical practice - General overview

Annals of Oncology

Volumn 15, Issue SUPPL. 4, 2004, Pages

  Daly, P A ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; GENE PRODUCT; MISMATCH REPAIR PROTEIN PMS2; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN MSH6; PROTEIN P53; PROTEIN RET; RALOXIFENE; SCATTER FACTOR RECEPTOR; TAMOXIFEN; VON HIPPEL LINDAU PROTEIN;

BREAST CANCER; CANCER GENETICS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; COLORECTAL CANCER; FAMILIAL CANCER; GENE MUTATION; GENETIC COUNSELING; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; KIDNEY CANCER; MAMMOGRAPHY; MELANOMA; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY; SARCOMA; STOMACH CARCINOMA; TREATMENT INDICATION;

GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PRACTICE GUIDELINES; RISK FACTORS; SYNDROME;

EID: 9744253010     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh915     Document Type: Review

References (48)

1. Khoury MJ, McCabe LL, McCabe EB. Population screening in the age of genomic medicine. N Engl J Med 2003; 348: 50-58.
2. Olopade OI, Pichert G. Cancer genetics in oncology practice. Ann Oncol 2001; 12: 895-908.
3. Hartmann LC, Schaid DJ, Woods JE et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84.
4. Meijers-Heijboer H, van Geel B, van Putten WLJ et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA 1 or BRCA 2 mutation. N Engl J Med 2001; 345: 159-164.
5. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingooophorectomy in women with a BRCA 1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609-1615.
6. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA 1 or 2 mutations. N Engl J Med 2002; 346: 1616-1622.
7. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA 1 or BRCA 2 mutation. J Clin Oncol 2003; 21: 1675-1681.
8. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277: 997-1003.
9. Scheuer L, Kauff N, Robson M et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20: 1260-1268.
10. Kuhl CK, Schmutzler RK, Leutner CC et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215: 267-279.
11. Stoutjesdijk MJ, Boetes C, Jager GJ et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93: 1095-1102.
12. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
13. Powles TJ, Ecles R, Ashely S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101.
14. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Prevention Study. Lancet 1998; 352: 93-97.
15. Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 2002; 360: 817-824.
16. Cuzick J, Powles T, Veronesi U et al. Over-view of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300.
17. Burke W, Petersen G, Lynch P et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer I. Hereditary nonpolyposis colon cancer. JAMA 1997; 277: 915-919.
18. Järvinen HJ, Aarnio M, Mustonen H et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118: 829-834.
19. Lynch HT. Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? Dis Colon Rectum 1996; 39: 109-110.
20. Machens A, Niccoli-Sire P, Hoegel J et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003; 349: 1517-1525.
21. Cote GJ, Gagel RF. Lessons learned from the management of a rare genetic cancer. N Engl J Med 2003; 349: 1566-1568.
22. de Snoo FA, Bergman W, Gruis NA. Familial melanoma: a complex disorder leading to controversy on DNA testing. Fam Cancer 2003; 2: 109-116.
23. Piver MS, Jishi MF, Tsukada Y et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993; 71: 2751-2755.
24. King MC, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA 1 and BRCA 2: National Surgical Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286: 2251-2256.
25. Burn J, Chapman PD, Mathers J et al. The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Eur J Cancer 1995; 31A: 385-386.
26. Tonelli F, Valanzano R, Messerini L, Ficari F. Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J Surg Oncol 2000; 74: 15-20.
27. Steinbach G, Lynch PM, Philips RKS et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952.
28. Lynch H, Lynch J. Genetic counseling for hereditary cancer. Oncology 1996; 10: 27-40.
29. Geller G, Botkin JR, Green MJ et al. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. JAMA 1997; 277: 1467-1474.
30. Lalloo F. Genetics for oncologists. In Hatchwell E (ed.): The Molecular Basis of Oncologic Disorders. London: Remedica 2002.
31. Fearon ER. Human cancer syndromes: Clues to the origin and nature of cancer. Science 1997; 278: 1043-1050.
32. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA 1 and BRCA 2: analysis of 10 000 individuals. J Clin Oncol 2002; 20: 1480-1490.
33. Hartge P, Struewing JP, Wacholder S et al. The prevalence of common BRCA 1 and BRCA 2 mutations among Ashkenazi Jews. Am J Hum Genet 1999; 64: 963-970.
34. Burke W. Genetic testing. N Engl J Med 2002; 347: 1867-1875.
35. Hoskins KF, Stopfer JE, Calzone KA et al. Assessment and counseling for women with a family history of breast cancer: A guide for clinicians. JAMA 1995; 273: 577-585.
36. Ford D, Easton DF, Bishop DT et al. Risks of cancer in BRCA 1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-695.
37. Easton DF, Steele L, Fields P et al. Cancer risks in two large breast cancer families linked to BRCA 2 on chromosome 13q12-13. Am J Hum Genet 1997; 61: 120-128.
38. Satagopan JM, Offit K, Foulkes W et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA 1 and BRCA 2 mutations. Cancer Epidemiol Biomarkers Prev 2001; 10: 467-473.
39. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA 1 and BRCA 2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
40. Breast Cancer Linkage Consortium. Cancer risks in BRCA 2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310-1316.
41. Couch GJ, DeShano ML, Blackwood MA et al. BRCA 1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl I Med 1997; 336: 1409-1415.
42. Shattuck-Eidens D, Oliphant A, McClure M et al. BRCA 1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997; 278: 1242-1250.
43. Berry DA, Parmigiani G, Sanchez J et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA 1 based on family history. J Natl Cancer Inst 1997; 89: 227-238.
44. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA 1 and BRCA 2. Am J Hum Genet 1998; 62: 145-158.
45. Matloff ET, Shappell H, Brierley K et al. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol 2000; 18: 2484-2492.
46. Pokorski RJ, Sanderson P, Bennett N et al. Insurance issues and genetic testing: challenges and recommendations: workshop no. 1. Cancer 1997; 80 (Suppl): 627.
47. The Ad Hoc Committee on Genetic Testing/Insurance Issues. Genetic testing and insurance. Am J Hum Genet 1995; 56: 327-331.
48. Croyle R, Achilles JS, Lerman C. Psychological aspects of cancer genetic testing. A research update for clinicians. Cancer 1997; 80: 569-575.